New York, NY (PRWEB) March 03, 2015
The BioArbitrage family of funds has announced the formation of BioArbitrage IV which will focus on rare diseases through the investment in promising orphan drug therapies. Since 2007, the family of BioArbitrage Funds has served as a disruptive investment vehicle to assist life science companies in the development of their innovation pipelines.
The funds operate in a unique manner as they drive strategic and tactical pipeline development with a keen eye on maximizing the ROI (return on investment), while minimizing the financial risk inherent with typical fund investment.
Operating side-by-side with Harrison Hayes, one of the premier, global life science advisory firms, the BioArbitrage family of funds enjoys a unique position having access to the ever evolving transactional and innovation healthcare ecosystem.
William. J. Smith, Managing Partner stated, "For our key investors, the fund becomes a strategic piece to building a robust innovation pipeline by delivering novel technologies and intellectual property to their portfolio. Through Harrison Hayes' contacts and database of IP opportunities (the proprietary Transforium Database), the fund has exposure to global technologies which are 'off the grid.' By identifying life science investments that are not "shopped' and being driven upwards by multiple investors, we are able to make selective decisions at reasonable valuations."
The $200 million BioArbitrage IV Fund is seeking new corporate and institutional investors to join previous Limited Partners.
Following the success of the previous three BioArbitrage funds, the Managing Partners chose to focus on the dynamic rare disease sector. With the passing of the Orphan Drug Act in 1983, the FDA established the Office of Orphan Product Development (OOPD) which gives incentives to biotech companies to develop promising products for the diagnosis, treatment and cure of rare diseases.